I M Longini Jr
Overview
Explore the profile of I M Longini Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1563
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Y, Zhang Y, Fang L, Halloran M, Ma M, Liang S, et al.
Euro Surveill
. 2015 Mar;
20(10):21056.
PMID: 25788253
To study human-to-human transmissibility of the avian influenza A (H7N9) virus in China, household contact information was collected for 125 index cases during the spring wave (February to May 2013),...
2.
Siddique A, Nair G, Alam M, Sack D, Huq A, Nizam A, et al.
Epidemiol Infect
. 2009 Aug;
138(3):347-52.
PMID: 19678971
During epidemics of cholera in two rural sites (Bakerganj and Mathbaria), a much higher proportion of patients came for treatment with severe dehydration than was seen in previous years. V....
3.
Halloran M, Longini Jr I
Am J Epidemiol
. 2001 Sep;
154(5):391-8.
PMID: 11532779
Methods of adjusting for bias in estimates due to mismeasured or missing covariates and outcomes through the use of validation sets have been developed in many types of health studies....
4.
Golm G, Halloran M, Longini Jr I
Biometrics
. 2001 Apr;
55(1):94-101.
PMID: 11318183
Exposure to infection information is important for estimating vaccine efficacy, but it is difficult to collect and prone to missingness and mismeasurement. We discuss study designs that collect detailed exposure...
5.
Datta S, Halloran M, Longini Jr I
Biometrics
. 2001 Apr;
55(3):792-8.
PMID: 11315008
In designing vaccine efficacy studies based on the secondary attack rate (SAR) or transmission probability in which both vaccine efficacy for susceptibility, VE(S), and vaccine efficacy for infectiousness, VE(I), are...
6.
Hudgens M, Satten G, Longini Jr I
Biometrics
. 2001 Mar;
57(1):74-80.
PMID: 11252621
We derive the nonparametric maximum likelihood estimate (NPMLE) of the cumulative incidence functions for competing risks survival data subject to interval censoring and truncation. Since the cumulative incidence function NPMLEs...
7.
Guihenneuc-Jouyaux C, Richardson S, Longini Jr I
Biometrics
. 2000 Sep;
56(3):733-41.
PMID: 10985209
Multistate models have been increasingly used to model natural history of many diseases as well as to characterize the follow-up of patients under varied clinical protocols. This modeling allows describing...
8.
Halloran M, Longini Jr I, Struchiner C
Epidemiol Rev
. 1999 Oct;
21(1):73-88.
PMID: 10520474
There are many different effects to consider when evaluating vaccines in the field. In this review, we have covered some of the various measures and issues related to study design...
9.
Longini Jr I, Hudgens M, Halloran M, Sagatelian K
Stat Med
. 1999 Feb;
18(1):53-68.
PMID: 9990692
We use a discrete-time non-homogeneous Markov chain to model data from augmented human immunodeficiency virus (HIV) vaccine trials. For this design, the study population consists of primary participants some of...
10.
Golm G, Halloran M, Longini Jr I
Stat Med
. 1998 Nov;
17(20):2335-52.
PMID: 9819831
Exposure to infection information is important for estimating vaccine efficacy, but it is difficult to collect and inherently prone to missingness and mismeasurement. It is, therefore, generally not feasible to...